|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-9-8
|
|
pubmed:abstractText |
The combination of gemcitabine and cisplatin is among the most active regimens for the treatment of NSCLC. However, the optimal dose and schedule for administration of the two drugs has not yet been determined. We investigated the activity and toxicity of a gemcitabine and split-dose cisplatin regimen in an outpatient setting for patients with advanced non-small cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
pubmed-author:AhnJin SeokJS,
pubmed-author:JungJoo YoungJY,
pubmed-author:KimHyo JungHJ,
pubmed-author:KimJung HanJH,
pubmed-author:KwonJung HyeJH,
pubmed-author:LeeDong HunDH,
pubmed-author:LeeJung-AeJA,
pubmed-author:LeeKeun SeokKS,
pubmed-author:ParkYoung LeeYL,
pubmed-author:ShinHyun ChunHC,
pubmed-author:SongHun HoHH,
pubmed-author:ZangDae YoungDY
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
57-62
|
|
pubmed:meshHeading |
pubmed-meshheading:16884818-Adult,
pubmed-meshheading:16884818-Aged,
pubmed-meshheading:16884818-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16884818-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16884818-Cisplatin,
pubmed-meshheading:16884818-Deoxycytidine,
pubmed-meshheading:16884818-Female,
pubmed-meshheading:16884818-Humans,
pubmed-meshheading:16884818-Lung Neoplasms,
pubmed-meshheading:16884818-Male,
pubmed-meshheading:16884818-Middle Aged,
pubmed-meshheading:16884818-Survival Rate,
pubmed-meshheading:16884818-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine, Hallym University College of Medicine, Seoul, Republic of Korea. harricil@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
